* ClinicalTrials.gov
32. Brown, H.C., et al., Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.
Mol Ther Methods Clin Dev, 2014. 1: p. 14036. Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated
viral vector delivery - PubMed (nih.gov)
33. Doering, C.B., et al., Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem, 2004. 279(8): p. 6546-52. 37.
Identification of Porcine Coagulation Factor VIII Domains Responsible for High Level Expression via Enhanced Secretion* - Journal of Biological Chemistry (jbc.org)
37. Doering, C.B., et al., Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A. Hum Gene Ther,
2018. 29(10): p. 1183-1201. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A - PMC (nih.gov)